期刊文献+

Latexin在胃癌组织中的表达及临床意义 被引量:2

Expression of latexin in gastric cancer and its clinical significance
下载PDF
导出
摘要 目的探讨Latexin(LXN)蛋白在胃癌组织中的表达及其与胃癌临床病理特征和预后的关系。方法采用组织芯片和免疫组织化学技术检测143例胃癌及对应癌旁组织中LXN蛋白的表达情况,分析其与临床病理特征及总生存期(OS)的关系。结果胃癌组织中LXN的阳性表达率为60.1%(86/143),低于癌旁组织100.0%(143/143),差异有统计学意义(P<0.05)。LXN蛋白表达与N分期(P=0.005)和组织分化(P=0.023)有关,与年龄、性别、肿瘤大小、T分期、TNM分期无关。全组患者的中位OS为56.0个月;LXN阳性表达者的中位OS为79.5个月,长于阴性表达者的27.0个月(P<0.05)。多因素分析显示仅肿瘤大小是影响胃癌预后的独立因素(P=0.018)。结论 LXN在胃癌组织中表达下调,且与部分临床病理特征有关,在一定程度上反映了胃癌的不良预后。 Objective To investigate the expression of latexin( LXN) in gastric cancer and determine the relationship of its expression with clinical features and prognosis. Methods The expression level of LXN was detected by tissue microarray technology and immunohistochemistry in 143 cases of gastric cancer and paired adjacent normal tissues. The relationship between the expression of LXN and clinical parameters were analyzed as well as overall survival( OS). Results The positive rate of LXN in gastric cancer tissues was 60. 1%( 86 /143),lower than 100. 0%( 143 /143) of para-carcinoma tissues( P〈0. 05). A significant correlation was observed between the expression of LXN and N stage( P = 0. 005),tumor differentiation( P = 0. 023),but not with age,gender,tumor size,T stage and TNM stage. The medium OS of 143 patients was 56. 0 months,and for the patients with LXN negative expression was27. 0 months,shorter than 79. 5 months of LXN positive expression( P〈0. 05). Multivariate analysis revealed that tumor size was the independent prognostic factor in gastric cancer patients( P = 0. 018). Conclusion LXN is down-regulated in gastric cancer and may relate to tumorgenesis and development. Loss of LXN expression is associated with the poor prognosis of gastric cancer.
出处 《临床肿瘤学杂志》 CAS 2015年第11期1006-1009,共4页 Chinese Clinical Oncology
关键词 组织芯片 Latexin(LXN) 胃癌 Tissue microarray Latexin(LXN) Gastric cancer
  • 相关文献

参考文献12

  • 1顾小强,武清.Latexin在食管鳞癌组织中的表达及其临床价值[J].临床肿瘤学杂志,2015,20(7):607-610. 被引量:2
  • 2Aagaard A, Listwan P, Cowieson N, et al. An inflammatory role for the mammalian carboxypeptidase inhibitor latexin : relationship to cystatins and the tumor suppressor TIG1 [ J ]. Structure(Camb), 2005,13(2) : 309-317.
  • 3Zhang H, Ren Y, Pang DY, et al. Clinical implications of AGBL2 expression and its inhibitor latexin in breast cancer[ J]. World J Surg Oncol, 2014, 12(1) : 142-148.
  • 4Xue ZX, Zheng JH, Zheng ZQ, et al. Latexin inhibits the prolif- eration of CD133 + miapaca-2 pancreatic cancer stem-like cells [J].World J Surg Oncol, 2014, 12(1) : 404-414.
  • 5Muthusamy V, Premi S, Soper C, et al. The hematopoietic stem cellregulatory gene latexin has tumor-suppressive properties in malignant melanoma [ J ]. J Invest Dermatol, 2013, 133 ( 7 ) :1827-1833.
  • 6AbdElmageed ZY, Moroz K, Kandil E. Clinical significance of CD146 and latexinduringdifferent stages of thyroid cancer [ J ]. Mol Cell Biochem, 2013, 381 ( 1 ) : 95-103.
  • 7Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J]. CA Cancer J Clin, 2011,61(2) :69-90.
  • 8吴成利,王咏梅,王革芳,于观贞,王杰军.乙醛脱氢酶1A1在胃癌组织中的表达及其临床意义[J].临床肿瘤学杂志,2014,19(11):992-995. 被引量:6
  • 9Song ZC, Liu WY, Xiao Y, et al. PRRll is a prognostic marker and potential oncogene in patients with gastric cancer [ J/OL ]. PLoS One, 2015 [ 2015-10-02 ]. http ://www. ncbi. nlm. nih. gov! pubmed/26252227.
  • 10Liang Y, Zant GV. Aging stem cells, latexin and longevity [ J ]. Exp Cell Res, 2008, 314(9) : 1962-1972.

二级参考文献13

  • 1Yuwei Zhang.Epidemiology of esophageal cancer[J].World Journal of Gastroenterology,2013,19(34):5598-5606. 被引量:81
  • 2Jemal A, Bray F, Center MM, et al.Global cancer statistics[ J]. CA Cancer J Clin,2011,61(2) :69-90.
  • 3Komatsu Y, Takahashi Y, Kimura Y, et al. Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301) [J]. Anticancer Drug,2011,22(6) : 576-583.
  • 4Bang Y J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(TOGA) : a phase 3, openlabel, randomized con- trolled trial[ J ]. Lancet,2010,376(9742) : 687-697.
  • 5Qian X, Wagner S, Ma C, et al. Prognostic significance of AL- DH1Al-positive cancer stem ceils in patients with locally ad- vanced, metastasized head and neck squamous cell carcinoma [ J]. J Cancer Res Clin Oncol,2014,140(7) : 1151-1158.
  • 6Keymoosi H1, Gheytanchi E, Asgari M, et al. ALDH1 in combi- nation with CD44 as putative cancer stem cell markers are corre- lated with poor prognosis in urothelial carcinoma of the urinary bladder[ J 1. Asian Pac J Cancer Prey,2014,15 ( 5 ) : 2013-2020.
  • 7Xing Y, Luo DY, Long MY, et al. High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma [ J 1. World J Surg 0ncol,2014,12:29.
  • 8Blot W J, Devesa SS, Kneller RW, et al.Rising incidence of ade- nocarcinoma of the esophagus and gastric cardia [ J ]. JAMA, 1991,265(10) : 1287-1289.
  • 9Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis[J]. Cancer, 2000,88(4) :921-932.
  • 10Theuer CP, Kurosaki T, Ziogas A, et al. Asian patients with gas- tric carcinoma in the United States exhibit unique clinical features and superior overall and cancer specific survival rates [ J ]. Cancer,2000,89(9) : 1883-1892.

共引文献6

同被引文献9

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部